留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

视网膜下膜取出术治疗Vogt-小柳-原田病合并黄斑区视网膜下膜的临床疗效

赵潺 张美芬 董方田

赵潺, 张美芬, 董方田. 视网膜下膜取出术治疗Vogt-小柳-原田病合并黄斑区视网膜下膜的临床疗效[J]. 协和医学杂志, 2013, 4(2): 109-112. doi: 10.3969/j.issn.1674-9081.2013.02.005
引用本文: 赵潺, 张美芬, 董方田. 视网膜下膜取出术治疗Vogt-小柳-原田病合并黄斑区视网膜下膜的临床疗效[J]. 协和医学杂志, 2013, 4(2): 109-112. doi: 10.3969/j.issn.1674-9081.2013.02.005
Chan ZHAO, Mei-fen ZHANG, Fang-tian DONG. Efficacy of Surgical Removal of Subretinal Fibrosis in Patients with Vogt-Koyanagi-Harada Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(2): 109-112. doi: 10.3969/j.issn.1674-9081.2013.02.005
Citation: Chan ZHAO, Mei-fen ZHANG, Fang-tian DONG. Efficacy of Surgical Removal of Subretinal Fibrosis in Patients with Vogt-Koyanagi-Harada Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(2): 109-112. doi: 10.3969/j.issn.1674-9081.2013.02.005

视网膜下膜取出术治疗Vogt-小柳-原田病合并黄斑区视网膜下膜的临床疗效

doi: 10.3969/j.issn.1674-9081.2013.02.005
详细信息
    通讯作者:

    张美芬 电话:010-69156351, E-mail:meifen_zhang@hotmail.com

    董方田 电话:010-69156351, E-mail:d_fangtian@163.com

  • 中图分类号: R779.62;R773.4

Efficacy of Surgical Removal of Subretinal Fibrosis in Patients with Vogt-Koyanagi-Harada Disease

More Information
  • 摘要:   目的  观察视网膜下膜取出术治疗Vogt-小柳-原田病(Vogt-Koyanagi-Harada disease, VKH)合并黄斑区视网膜下膜的临床疗效。  方法  回顾性分析2008年1月至2011年12月在北京协和医院行玻璃体切除+视网膜下膜取出术的VKH患者的临床资料。  结果  3例VKH患者共4只眼接受了视网膜下膜取出术。患者中男2例, 女1例, 平均年龄40.7岁(31~48岁)。接受视网膜下膜取出术的4只眼中, 术前均有黄斑区视网膜下膜, 最佳矫正视力在光感至0.06之间; 2只眼术前无白内障, 1只眼合并轻度白内障, 1只眼合并重度白内障。所有患眼在术中均行玻璃体大部切除+视网膜切开+视网膜下膜取出术; 合并重度白内障的患眼术中行后路晶体切除术; 1只眼术中行C3F8填充, 另3只眼行硅油填充。所有患者围术期无严重并发症。随访过程中, 3只行硅油填充术的患眼均行二期硅油取出术, 术后随诊过程中均无视网膜脱离。2只术前无白内障的患眼在随访过程中均出现白内障并影响视力, 均成功施行白内障超声乳化吸除术+人工晶体植入术。术前有轻度白内障的患眼行硅油取出术的同时行后路晶体切除+人工晶体植入术。末次随诊在最后一次手术后1~6个月, 平均3.8个月, 均无活动性的前后节炎症。4只眼的末次随诊视力较第1次术前均有所提高。  结论  视网膜下膜取出术是治疗VKH合并黄斑区视网膜下膜的有效方法; 下膜取出术后常出现白内障, 需要手术治疗。
  • 图  1  患者2左眼的术前(A)及术后(B)彩色眼底像

    表  1  行视网膜下膜取出术的Vogt-小柳-原田病患者的临床资料

  • [1] Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome[J]. Surv Ophthalmol, 1995, 39:265-292. doi:  10.1016/S0039-6257(05)80105-5
    [2] Rajendram R, Evans M, Rao NA. Vogt-Koyanagi-Harada disease[J]. Int Ophthalmol Clin, 2005, 45:115-134. https://pubmed.ncbi.nlm.nih.gov/27241814/
    [3] Andreoli CM, Foster CS. Vogt-Koyanagi-Harada disease[J]. Int Ophthalmol Clin, 2006, 46:111-122. doi:  10.1097/00004397-200604620-00011
    [4] Yang P, Ren Y, Li B, et al. Clinical characteristics of VogtKoyanagi-Harada syndrome in Chinese patients[J]. Ophthalmology, 2007, 114:606-614. doi:  10.1016/j.ophtha.2006.07.040
    [5] 杨培增, 张震, 王红, 等.葡萄膜炎的临床类型及病因探讨[J].中华眼底病杂志, 2002, 18:253-255. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhydb200204001
    [6] Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease[J]. Am J Ophthalmol, 2001, 131:599-606. doi:  10.1016/S0002-9394(01)00937-0
    [7] Lertsumitkul S, Whitcup SM, Nussenblatt RB, et al. Subretinal fibrosis and choroidal neovascularization in Vogt-Koyanagi-Harada syndrome[J]. Graefes Arch Clin Exp Ophthalmol, 1999, 237:1039-1045. doi:  10.1007/s004170050342
    [8] Zhao C, Zhang MF, Dong FT, et al. Spectral domain optical coherence tomography of Vogt-Koyanagi-Harada disease:novel findings and new insights into the pathogenesis[J]. Chin Med Sci J, 2012, 27:29-34. doi:  10.1016/S1001-9294(12)60019-4
    [9] Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease:report of an international committee on nomenclature[J]. Am J Ophthalmol, 2001, 131:647-652. doi:  10.1016/S0002-9394(01)00925-4
    [10] Kuo IC, Rechdouni A, Rao NA, et al. Subretinal fibrosis in patients with Vogt-Koyanagi-Harada disease[J]. Ophthalmology, 2000, 107:1721-1728. doi:  10.1016/S0161-6420(00)00244-X
    [11] Bykhovskaya I, Thorne JE, Kempen JH, et al. Vogt-Koyanagi-Harada disease:clinical outcomes[J]. Am J Ophthalmol, 2005, 140:674-678. https://www.ncbi.nlm.nih.gov/pubmed/16226518
    [12] Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease[J]. Semin Ophthalmol, 2005, 20:183-190. doi:  10.1080/08820530500232126
    [13] Tugal-Tutkun I, Ozyazgan Y, Akova YA, et al. The spectrum of Vogt-Koyanagi-Harada disease in Turkey:VKH in Turkey[J]. Int Ophthalmol, 2007, 27:117-123. doi:  10.1007/s10792-006-9001-1
    [14] Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition[J]. J Clin Invest, 2009, 119:1420-1428. doi:  10.1172/JCI39104
    [15] Saika S, Yamanaka O, Sumioka T, et al. Fibrotic disorders in the eye:targets of gene therapy[J]. Prog Retin Eye Res, 2008, 27:177-196. doi:  10.1016/j.preteyeres.2007.12.002
    [16] 董方田, 张承芳.黄斑下脉络膜新生血管膜的手术治疗及随访观察[J].中华眼科杂志, 1997, 33:251-254. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyk199704004
    [17] Gass JD. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes[J]. Am J Ophthalmol, 1994, 118:285-298. doi:  10.1016/S0002-9394(14)72951-4
    [18] Grossniklaus HE, Gass JD. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes[J]. Am J Ophthalmol, 1998, 126:59-69. doi:  10.1016/S0002-9394(98)00145-7
    [19] Rao NA. Pathology of Vogt-Koyanagi-Harada disease[J]. Int Ophthalmol, 2007, 27:81-85. doi:  10.1007/s10792-006-9029-2
  • 加载中
图(1) / 表(1)
计量
  • 文章访问数:  115
  • HTML全文浏览量:  24
  • PDF下载量:  4
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-03-25
  • 刊出日期:  2013-04-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!